

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-72. (Canceled)

73. (Previously Presented) An isolated polypeptide comprising SEQ ID NO: 392.

74.-75. (Canceled)

76. (Currently Amended) An isolated polypeptide comprising ~~amino acid residues 1-27 of~~ SEQ ID NO: 392, or a variant thereof having at least 90% identity to SEQ ID NO: 392, wherein said polypeptide variant reacts with an antibody that specifically binds the polypeptide of SEQ ID NO: 392.

77. (Currently Amended) An isolated polypeptide comprising SEQ ID NO: 392 or a variant thereof containing only conservative amino acid substitutions and an amino acid sequence having at least 90% identity to SEQ ID NO: 392, wherein said ~~polypeptide variant~~ reacts with an antibody that specifically binds the polypeptide of SEQ ID NO: 392.

78. (Currently Amended) A fusion polypeptide comprising a polypeptide according to any one of claims ~~763~~-77.

79. (Currently Amended) A composition comprising a polypeptide according to any one of claims ~~763~~-77 and at least one physiologically acceptable excipient.

80. (Currently Amended) A composition comprising a polypeptide according to any one of claims ~~76~~3-77 and at least one adjuvant.

81. (Previously Presented) The composition of claim 80, wherein the adjuvant is selected from the group consisting of: an MPL, QS21 and AS-2.